While no anti-IFN-γ therapies are currently FDA-approved for autoimmune diseases, early-phase clinical trials in systemic lupus erythematosus, rheumatoid arthritis, and multiple sclerosis are ongoing. This evidence concerns the gene IFNG and rheumatoid arthritis.